Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Bio to Participate in Panel Discussion at TD Cowen’s 44th Annual Conference
Puma to Host Conference to Discuss Q4 and Full Year 2023 Financial Results
Puma Bio Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib
Puma Bio to Present at B. Riley Securities 4th Annual Oncology Conference
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib